SrasV1, PascalFrancis, Corpus, bibRecord, 000725

Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV

Identifieur interne : 000725 ( PascalFrancis/Corpus ); précédent : 000724; suivant : 000726

Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV

Auteurs : Ivanus Manopo ; LIQUN LU ; QIGAI HE ; LI LIAN CHEE ; Shzu-Wei Chan ; Jimmy Kwang

Source :

Journal of immunological methods [ 0022-1759 ] ; 2005.

RBID : Pascal:05-0121836

Descripteurs français

Pascal (Inist)
- Protéine, Immunofluorescence, Détection, Immunité humorale, Anticorps, Méthode immunologique, Syndrome respiratoire aigu sévère.

English descriptors

KwdEn :
- Antibody, Detection, Humoral immunity, Immunofluorescence, Immunological method, Protein, Severe acute respiratory syndrome.

Abstract

Previously, we have identified a truncated antigenic fragment named protein C [441 to 700 amino acids (a.a.)] as the immunodominant fragment of Spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). We have now successfully expressed protein C using the baculovirus system in S. frugiperda (Sf-9) cells. This recombinant baculovirus expressing protein C was first characterized using five SARS convalescent human sera and five normal human sera. The results showed that protein C is an authentic antigen against SARS-CoV antibody. Our Spike protein-based immunoflourescence assay (IFA) based on this recombinant baculovirus-Sf-9 system was further assessed with a panel of 163 clinical samples collected during the SARS epidemic in Singapore, which include samples from 21 clinically confirmed SARS, 42 non-SARS patient sera, and 100 normal sera. The results were compared to a commercial SARS IFA kit (EUROIMMUN, Germany) and a conventional IFA test performed in Singapore General Hospital. All of the 21 SARS-positive serum samples could be recognized by our IFA, giving a specificity and sensitivity of 100%, which was compatible with both whole virus-based IFA assays. No cross-reactivity with serum samples against infectious bronchitis virus (IBV) and transmissible gastroenteritis virus (TGEV) were detected in our assays. Thus, our Spike protein-based IFA could offer a safer procedure which can be performed in a BSL-2 laboratory as it could mimic the whole virus based-IFA without any loss of sensitivity and specificity. It is also more user-friendly and cost-effective than the whole virus-based IFA.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-1759`
A02	`01`			`@0 JIMMBG`
A03		`1`		`@0 J. immunol. methods`
A05				`@2 296`
A06				`@2 1-2`
A08	`01`	`1`	`ENG`	`@1 Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV`
A11	`01`	`1`		`@1 MANOPO (Ivanus)`
A11	`02`	`1`		`@1 LIQUN LU`
A11	`03`	`1`		`@1 QIGAI HE`
A11	`04`	`1`		`@1 LI LIAN CHEE`
A11	`05`	`1`		`@1 CHAN (Shzu-Wei)`
A11	`06`	`1`		`@1 KWANG (Jimmy)`
A14	`01`			`@1 Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore @2 117604 Singapore @3 SGP @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 37-44`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 15654 @5 354000126735630050`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 18 ref.`
A47	`01`	`1`		`@0 05-0121836`
A60				`@1 P @3 PR`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of immunological methods`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Previously, we have identified a truncated antigenic fragment named protein C [441 to 700 amino acids (a.a.)] as the immunodominant fragment of Spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). We have now successfully expressed protein C using the baculovirus system in S. frugiperda (Sf-9) cells. This recombinant baculovirus expressing protein C was first characterized using five SARS convalescent human sera and five normal human sera. The results showed that protein C is an authentic antigen against SARS-CoV antibody. Our Spike protein-based immunoflourescence assay (IFA) based on this recombinant baculovirus-Sf-9 system was further assessed with a panel of 163 clinical samples collected during the SARS epidemic in Singapore, which include samples from 21 clinically confirmed SARS, 42 non-SARS patient sera, and 100 normal sera. The results were compared to a commercial SARS IFA kit (EUROIMMUN, Germany) and a conventional IFA test performed in Singapore General Hospital. All of the 21 SARS-positive serum samples could be recognized by our IFA, giving a specificity and sensitivity of 100%, which was compatible with both whole virus-based IFA assays. No cross-reactivity with serum samples against infectious bronchitis virus (IBV) and transmissible gastroenteritis virus (TGEV) were detected in our assays. Thus, our Spike protein-based IFA could offer a safer procedure which can be performed in a BSL-2 laboratory as it could mimic the whole virus based-IFA without any loss of sensitivity and specificity. It is also more user-friendly and cost-effective than the whole virus-based IFA.
C02	`01`	`X`		`@0 002A06B06`
C03	`01`	`X`	`FRE`	`@0 Protéine @5 05`
C03	`01`	`X`	`ENG`	`@0 Protein @5 05`
C03	`01`	`X`	`SPA`	`@0 Proteína @5 05`
C03	`02`	`X`	`FRE`	`@0 Immunofluorescence @5 06`
C03	`02`	`X`	`ENG`	`@0 Immunofluorescence @5 06`
C03	`02`	`X`	`SPA`	`@0 Inmunofluorescencia @5 06`
C03	`03`	`X`	`FRE`	`@0 Détection @5 07`
C03	`03`	`X`	`ENG`	`@0 Detection @5 07`
C03	`03`	`X`	`SPA`	`@0 Detección @5 07`
C03	`04`	`X`	`FRE`	`@0 Immunité humorale @5 08`
C03	`04`	`X`	`ENG`	`@0 Humoral immunity @5 08`
C03	`04`	`X`	`SPA`	`@0 Inmunidad humoral @5 08`
C03	`05`	`X`	`FRE`	`@0 Anticorps @5 09`
C03	`05`	`X`	`ENG`	`@0 Antibody @5 09`
C03	`05`	`X`	`SPA`	`@0 Anticuerpo @5 09`
C03	`06`	`X`	`FRE`	`@0 Méthode immunologique @5 10`
C03	`06`	`X`	`ENG`	`@0 Immunological method @5 10`
C03	`06`	`X`	`SPA`	`@0 Método inmunológico @5 10`
C03	`07`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 14`
C03	`07`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 14`
C03	`07`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 14`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
N21				`@1 080`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0121836 INIST
ET :	Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV
AU :	MANOPO (Ivanus); LIQUN LU; QIGAI HE; LI LIAN CHEE; CHAN (Shzu-Wei); KWANG (Jimmy)
AF :	Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore/117604 Singapore/Singapour (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.)
DT :	Publication en série; Papier de recherche; Niveau analytique
SO :	Journal of immunological methods; ISSN 0022-1759; Coden JIMMBG; Pays-Bas; Da. 2005; Vol. 296; No. 1-2; Pp. 37-44; Bibl. 18 ref.
LA :	Anglais
EA :	Previously, we have identified a truncated antigenic fragment named protein C [441 to 700 amino acids (a.a.)] as the immunodominant fragment of Spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). We have now successfully expressed protein C using the baculovirus system in S. frugiperda (Sf-9) cells. This recombinant baculovirus expressing protein C was first characterized using five SARS convalescent human sera and five normal human sera. The results showed that protein C is an authentic antigen against SARS-CoV antibody. Our Spike protein-based immunoflourescence assay (IFA) based on this recombinant baculovirus-Sf-9 system was further assessed with a panel of 163 clinical samples collected during the SARS epidemic in Singapore, which include samples from 21 clinically confirmed SARS, 42 non-SARS patient sera, and 100 normal sera. The results were compared to a commercial SARS IFA kit (EUROIMMUN, Germany) and a conventional IFA test performed in Singapore General Hospital. All of the 21 SARS-positive serum samples could be recognized by our IFA, giving a specificity and sensitivity of 100%, which was compatible with both whole virus-based IFA assays. No cross-reactivity with serum samples against infectious bronchitis virus (IBV) and transmissible gastroenteritis virus (TGEV) were detected in our assays. Thus, our Spike protein-based IFA could offer a safer procedure which can be performed in a BSL-2 laboratory as it could mimic the whole virus based-IFA without any loss of sensitivity and specificity. It is also more user-friendly and cost-effective than the whole virus-based IFA.
CC :	002A06B06
FD :	Protéine; Immunofluorescence; Détection; Immunité humorale; Anticorps; Méthode immunologique; Syndrome respiratoire aigu sévère
FG :	Virose; Infection
ED :	Protein; Immunofluorescence; Detection; Humoral immunity; Antibody; Immunological method; Severe acute respiratory syndrome
EG :	Viral disease; Infection
SD :	Proteína; Inmunofluorescencia; Detección; Inmunidad humoral; Anticuerpo; Método inmunológico; Síndrome respiratorio agudo severo
LO :	INIST-15654.354000126735630050
ID :	05-0121836

Links to Exploration step

Pascal:05-0121836

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV</title>
<author><name sortKey="Manopo, Ivanus" sort="Manopo, Ivanus" uniqKey="Manopo I" first="Ivanus" last="Manopo">Ivanus Manopo</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liqun Lu" sort="Liqun Lu" uniqKey="Liqun Lu" last="Liqun Lu">LIQUN LU</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qigai He" sort="Qigai He" uniqKey="Qigai He" last="Qigai He">QIGAI HE</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li Lian Chee" sort="Li Lian Chee" uniqKey="Li Lian Chee" last="Li Lian Chee">LI LIAN CHEE</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Shzu Wei" sort="Chan, Shzu Wei" uniqKey="Chan S" first="Shzu-Wei" last="Chan">Shzu-Wei Chan</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kwang, Jimmy" sort="Kwang, Jimmy" uniqKey="Kwang J" first="Jimmy" last="Kwang">Jimmy Kwang</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0121836</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0121836 INIST</idno>
<idno type="RBID">Pascal:05-0121836</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000725</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV</title>
<author><name sortKey="Manopo, Ivanus" sort="Manopo, Ivanus" uniqKey="Manopo I" first="Ivanus" last="Manopo">Ivanus Manopo</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liqun Lu" sort="Liqun Lu" uniqKey="Liqun Lu" last="Liqun Lu">LIQUN LU</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qigai He" sort="Qigai He" uniqKey="Qigai He" last="Qigai He">QIGAI HE</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li Lian Chee" sort="Li Lian Chee" uniqKey="Li Lian Chee" last="Li Lian Chee">LI LIAN CHEE</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Shzu Wei" sort="Chan, Shzu Wei" uniqKey="Chan S" first="Shzu-Wei" last="Chan">Shzu-Wei Chan</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kwang, Jimmy" sort="Kwang, Jimmy" uniqKey="Kwang J" first="Jimmy" last="Kwang">Jimmy Kwang</name>
<affiliation><inist:fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of immunological methods</title>
<title level="j" type="abbreviated">J. immunol. methods</title>
<idno type="ISSN">0022-1759</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of immunological methods</title>
<title level="j" type="abbreviated">J. immunol. methods</title>
<idno type="ISSN">0022-1759</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody</term>
<term>Detection</term>
<term>Humoral immunity</term>
<term>Immunofluorescence</term>
<term>Immunological method</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Protéine</term>
<term>Immunofluorescence</term>
<term>Détection</term>
<term>Immunité humorale</term>
<term>Anticorps</term>
<term>Méthode immunologique</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Previously, we have identified a truncated antigenic fragment named protein C [441 to 700 amino acids (a.a.)] as the immunodominant fragment of Spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). We have now successfully expressed protein C using the baculovirus system in S. frugiperda (Sf-9) cells. This recombinant baculovirus expressing protein C was first characterized using five SARS convalescent human sera and five normal human sera. The results showed that protein C is an authentic antigen against SARS-CoV antibody. Our Spike protein-based immunoflourescence assay (IFA) based on this recombinant baculovirus-Sf-9 system was further assessed with a panel of 163 clinical samples collected during the SARS epidemic in Singapore, which include samples from 21 clinically confirmed SARS, 42 non-SARS patient sera, and 100 normal sera. The results were compared to a commercial SARS IFA kit (EUROIMMUN, Germany) and a conventional IFA test performed in Singapore General Hospital. All of the 21 SARS-positive serum samples could be recognized by our IFA, giving a specificity and sensitivity of 100%, which was compatible with both whole virus-based IFA assays. No cross-reactivity with serum samples against infectious bronchitis virus (IBV) and transmissible gastroenteritis virus (TGEV) were detected in our assays. Thus, our Spike protein-based IFA could offer a safer procedure which can be performed in a BSL-2 laboratory as it could mimic the whole virus based-IFA without any loss of sensitivity and specificity. It is also more user-friendly and cost-effective than the whole virus-based IFA.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-1759</s0>
</fA01>
<fA02 i1="01"><s0>JIMMBG</s0>
</fA02>
<fA03 i2="1"><s0>J. immunol. methods</s0>
</fA03>
<fA05><s2>296</s2>
</fA05>
<fA06><s2>1-2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MANOPO (Ivanus)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LIQUN LU</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>QIGAI HE</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LI LIAN CHEE</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CHAN (Shzu-Wei)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KWANG (Jimmy)</s1>
</fA11>
<fA14 i1="01"><s1>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore</s1>
<s2>117604 Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>37-44</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>15654</s2>
<s5>354000126735630050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>18 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0121836</s0>
</fA47>
<fA60><s1>P</s1>
<s3>PR</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of immunological methods</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Previously, we have identified a truncated antigenic fragment named protein C [441 to 700 amino acids (a.a.)] as the immunodominant fragment of Spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). We have now successfully expressed protein C using the baculovirus system in S. frugiperda (Sf-9) cells. This recombinant baculovirus expressing protein C was first characterized using five SARS convalescent human sera and five normal human sera. The results showed that protein C is an authentic antigen against SARS-CoV antibody. Our Spike protein-based immunoflourescence assay (IFA) based on this recombinant baculovirus-Sf-9 system was further assessed with a panel of 163 clinical samples collected during the SARS epidemic in Singapore, which include samples from 21 clinically confirmed SARS, 42 non-SARS patient sera, and 100 normal sera. The results were compared to a commercial SARS IFA kit (EUROIMMUN, Germany) and a conventional IFA test performed in Singapore General Hospital. All of the 21 SARS-positive serum samples could be recognized by our IFA, giving a specificity and sensitivity of 100%, which was compatible with both whole virus-based IFA assays. No cross-reactivity with serum samples against infectious bronchitis virus (IBV) and transmissible gastroenteritis virus (TGEV) were detected in our assays. Thus, our Spike protein-based IFA could offer a safer procedure which can be performed in a BSL-2 laboratory as it could mimic the whole virus based-IFA without any loss of sensitivity and specificity. It is also more user-friendly and cost-effective than the whole virus-based IFA.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A06B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Protéine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Protein</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Proteína</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Immunofluorescence</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Immunofluorescence</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Inmunofluorescencia</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Détection</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Detection</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Detección</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Immunité humorale</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Humoral immunity</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Inmunidad humoral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Anticorps</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antibody</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Anticuerpo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Méthode immunologique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Immunological method</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Método inmunológico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>080</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0121836 INIST</NO>
<ET>Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV</ET>
<AU>MANOPO (Ivanus); LIQUN LU; QIGAI HE; LI LIAN CHEE; CHAN (Shzu-Wei); KWANG (Jimmy)</AU>
<AF>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research link, National University of singapore/117604 Singapore/Singapour (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.)</AF>
<DT>Publication en série; Papier de recherche; Niveau analytique</DT>
<SO>Journal of immunological methods; ISSN 0022-1759; Coden JIMMBG; Pays-Bas; Da. 2005; Vol. 296; No. 1-2; Pp. 37-44; Bibl. 18 ref.</SO>
<LA>Anglais</LA>
<EA>Previously, we have identified a truncated antigenic fragment named protein C [441 to 700 amino acids (a.a.)] as the immunodominant fragment of Spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). We have now successfully expressed protein C using the baculovirus system in S. frugiperda (Sf-9) cells. This recombinant baculovirus expressing protein C was first characterized using five SARS convalescent human sera and five normal human sera. The results showed that protein C is an authentic antigen against SARS-CoV antibody. Our Spike protein-based immunoflourescence assay (IFA) based on this recombinant baculovirus-Sf-9 system was further assessed with a panel of 163 clinical samples collected during the SARS epidemic in Singapore, which include samples from 21 clinically confirmed SARS, 42 non-SARS patient sera, and 100 normal sera. The results were compared to a commercial SARS IFA kit (EUROIMMUN, Germany) and a conventional IFA test performed in Singapore General Hospital. All of the 21 SARS-positive serum samples could be recognized by our IFA, giving a specificity and sensitivity of 100%, which was compatible with both whole virus-based IFA assays. No cross-reactivity with serum samples against infectious bronchitis virus (IBV) and transmissible gastroenteritis virus (TGEV) were detected in our assays. Thus, our Spike protein-based IFA could offer a safer procedure which can be performed in a BSL-2 laboratory as it could mimic the whole virus based-IFA without any loss of sensitivity and specificity. It is also more user-friendly and cost-effective than the whole virus-based IFA.</EA>
<CC>002A06B06</CC>
<FD>Protéine; Immunofluorescence; Détection; Immunité humorale; Anticorps; Méthode immunologique; Syndrome respiratoire aigu sévère</FD>
<FG>Virose; Infection</FG>
<ED>Protein; Immunofluorescence; Detection; Humoral immunity; Antibody; Immunological method; Severe acute respiratory syndrome</ED>
<EG>Viral disease; Infection</EG>
<SD>Proteína; Inmunofluorescencia; Detección; Inmunidad humoral; Anticuerpo; Método inmunológico; Síndrome respiratorio agudo severo</SD>
<LO>INIST-15654.354000126735630050</LO>
<ID>05-0121836</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000725 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000725 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0121836
   |texte=   Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV

Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri